SM 04646

Drug Profile

SM 04646

Alternative Names: SM-04646

Latest Information Update: 04 Nov 2016

Price : $50

At a glance

  • Originator Samumed
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis

Most Recent Events

  • 04 Nov 2016 Samumed plans a phase II trial for Idiopathic pulmonary fibrosis
  • 01 Nov 2016 Samumed completes a phase I trial in Idiopathic pulmonary fibrosis (In healthy volunteers) in Australia (Intranasal, Inhalant)
  • 10 Nov 2015 Phase-I clinical trials in Idiopathic pulmonary fibrosis (In healthy volunteers) in Australia (Intranasal, Inhalant) (ACTRN12615001349538)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top